Conference abstract

Evaluation of apolipoproteins A1 and B in immunoturbidimetric method in a diabetic´s group in Cameroon

Pan African Medical Journal - Conference Proceedings. 2021:11(38).01 Feb 2021.
doi: 10.11604/pamj-cp.2021.11.38.1005
Archived on: 01 Feb 2021
Contact the corresponding author
Keywords: Apolipoprotein A1 and B, type 1 and 2 diabetes, lipids profiles, glycosylated haemoglobin

Evaluation of apolipoproteins A1 and B in immunoturbidimetric method in a diabetic´s group in Cameroon

Louis Hervé Nnoma1,&, Dieudonné Adiogo2, Nda Mefo’o3, Siméon Choukem3

1Centre Pasteur du Cameroun, Yaoundé, Cameroun, 2Faculté de Médecine et des Sciences Pharmaceutiques Université de Douala, Cameroun, 3Hôpital Général de Douala, Douala, Cameroun

&Corresponding author

Introduction: with an estimated morbidity of 19.8 million dollars in Africa in 2013, and a projected increase of 41.5 million in 2035, diabetes is at the top of the list of cardiovascular diseases. In Cameroon, the therapeutic approach of diabetic patients rarely includes the contribution of apolipoproteins A1 and B despite their expression in lipid metabolism. The exploration of apolipoproteins A1 and B, thus brought an added value in the biological and therapeutic follow-up of these patients, in this fact we proposed to evaluate the impact of these markers in the biological assessment of the diabetic subject in Cameroon. Methods: a consecutive recruitment of 60 known diabetic patients was carried out for 5 months in the Biochemistry laboratory of Douala General Hospital to constitute our cohort. This prospective analytical study made it possible to obtain extensive glycemic and lipid balance data on samples obtained after centrifugation at 2500 g / min for 10 minutes by immunoturbidimetric method on Cobas C311 automata (ROCHE). The data collected was analyzed and tested for linear correlation statistics from the SPSS software. Results: 53/60 (88.3%) of type 2 and 7/60 (11.7%) type 1 diabetics were identified. 33.3% of these patients had diabetes for more than 120 months, 26.7% had a BMI between [25-30[ and 61.7% had known hypertension. The average values of apolipoproteins obtained were 1.40 ± 0.35 g / l and 0.90 ± 0.28 g / l respectively for Apo A1 and Apo B for an Apo B / Apo A1 ratio = 0.687 ± 0.326 > 0.641 (normal value). The analysis of the point cloud graph between ApoB / Apo A1 and glycosylated haemoglobin allowed us to obtain a positive correlation (Pearson = 0.03, P-value = 0.77 >> 0.05). Conclusion: the results of this small study show us the involvement of apolipoproteins A1 and B as a valuable element in the follow-up of diabetic patients. In addition, the variation of the glycemic balance of our population seems to be a function of the value of the ratio Apo B / A1 thus confirming the importance of the dosage of these markers in diabetics patients.